×
About 7,920 results

ALLMedicine™ Angioedema Center

Research & Reviews  3,349 results

Impact of lanadelumab on health-related quality of life in patients with hereditary ang...
https://doi.org/10.1111/all.14680
Allergy Lumry WR, Weller K et. al.

Dec 1st, 2020 - An objective of the phase 3 HELP Study was to investigate the effect of lanadelumab on health-related quality of life (HRQoL) in patients with hereditary angioedema (HAE). Patients with HAE-1/2 received either lanadelumab 150 mg every 4 weeks (q4w...

Transient angioedema of the small bowel due to intravenous nonionic iodinated contrast ...
https://doi.org/10.1016/j.jpeds.2020.11.043
The Journal of Pediatrics; Wakabayashi T, Sasaoka Y et. al.

Nov 29th, 2020 - Transient angioedema of the small bowel due to intravenous nonionic iodinated contrast media.|2020|Wakabayashi T,Sasaoka Y,Sakai Y,Miyamoto S,Tsugawa T,|

Cold urticaria what we know and what we do not know.
https://doi.org/10.1111/all.14674
Allergy Maltseva N, Borzova E et. al.

Nov 29th, 2020 - Cold urticaria (ColdU) is a common form of chronic inducible urticaria characterised by the development of wheals, angioedema or both in response to cold exposure. Recent research and guideline updates have advanced our understanding and managemen...

Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in J...
https://doi.org/10.1111/all.14670
Allergy Ohsawa I, Honda D et. al.

Nov 28th, 2020 - With no approved treatments in Japan for the prevention of hereditary angioedema (HAE) attacks, there is a significant unmet need for long-term prophylactic therapies for Japanese patients with HAE. Berotralstat (BCX7353) is an oral, once-daily, h...

Acute urticaria in the infant.
https://doi.org/10.1111/pai.13350
Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology REFERENCES; Minasi D, Manti S et. al.

Nov 25th, 2020 - Urticaria is a mast cell-driven disease presenting with wheals, angioedema, or both. Acute urticaria (AU) lasts < 6 weeks. AU is a not common condition in newborns and infants since they are showing an immune system functionally insufficient. In n...

see more →

Guidelines  17 results

The international WAO/EAACI guideline for the management of hereditary angioedema-The 2...
https://doi.org/10.1111/all.13384
Allergy Maurer M, Magerl M et. al.

Jan 10th, 2018 - Hereditary Angioedema (HAE) is a rare and disabling disease. Early diagnosis and appropriate therapy are essential. This update and revision of the global guideline for HAE provides up-to-date consensus recommendations for the management of HAE. I...

BSACI guideline for the management of chronic urticaria and angioedema.
https://doi.org/10.1111/cea.12494
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology; Powell RJ, Leech SC et. al.

Feb 25th, 2015 - This guidance for the management of patients with chronic urticaria and angioedema has been prepared by the Standards of Care Committee of the British Society for Allergy and Clinical Immunology (BSACI). The guideline is based on evidence as well ...

The diagnosis and management of acute and chronic urticaria: 2014 update
https://www.aaaai.org/Aaaai/media/MediaLibrary/PDF%20Documents/Practice%20and%20Parameters/Urticaria-2014.pdf
Bernstein, J.

Apr 30th, 2014 - Theworkgroup was formed by the JTFPP to develop a practiceparameter to address the diagnosis and treatment of urticaria withor without angioedema. The chair, Jonathan Bernstein, MD,invited workgroup members to participate in the parameterdevelopme.

A consensus parameter for the evaluation and management of angioedema in the emergency ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4100605
Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine; Moellman JJ, Bernstein JA et. al.

Apr 15th, 2014 - Despite its relatively common occurrence and life-threatening potential, the management of angioedema in the emergency department (ED) is lacking in terms of a structured approach. It is paramount to distinguish the different etiologies of angioed...

A focused parameter update: hereditary angioedema, acquired C1 inhibitor deficiency, an...
https://doi.org/10.1016/j.jaci.2013.03.034
The Journal of Allergy and Clinical Immunology; Zuraw BL, Bernstein JA et. al.

Jun 3rd, 2013 - These parameters were developed by the Joint Task Force on Practice Parameters (JTFPP), representing the American Academy of Allergy, Asthma & Immunology (AAAAI); the American College of Allergy, Asthma & Immunology (ACAAI); and the Joint Council ...

see more →

Drugs  403 results see all →

Clinicaltrials.gov  3,909 results

Impact of lanadelumab on health-related quality of life in patients with hereditary ang...
https://doi.org/10.1111/all.14680
Allergy Lumry WR, Weller K et. al.

Dec 1st, 2020 - An objective of the phase 3 HELP Study was to investigate the effect of lanadelumab on health-related quality of life (HRQoL) in patients with hereditary angioedema (HAE). Patients with HAE-1/2 received either lanadelumab 150 mg every 4 weeks (q4w...

Transient angioedema of the small bowel due to intravenous nonionic iodinated contrast ...
https://doi.org/10.1016/j.jpeds.2020.11.043
The Journal of Pediatrics; Wakabayashi T, Sasaoka Y et. al.

Nov 29th, 2020 - Transient angioedema of the small bowel due to intravenous nonionic iodinated contrast media.|2020|Wakabayashi T,Sasaoka Y,Sakai Y,Miyamoto S,Tsugawa T,|

Cold urticaria what we know and what we do not know.
https://doi.org/10.1111/all.14674
Allergy Maltseva N, Borzova E et. al.

Nov 29th, 2020 - Cold urticaria (ColdU) is a common form of chronic inducible urticaria characterised by the development of wheals, angioedema or both in response to cold exposure. Recent research and guideline updates have advanced our understanding and managemen...

Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in J...
https://doi.org/10.1111/all.14670
Allergy Ohsawa I, Honda D et. al.

Nov 28th, 2020 - With no approved treatments in Japan for the prevention of hereditary angioedema (HAE) attacks, there is a significant unmet need for long-term prophylactic therapies for Japanese patients with HAE. Berotralstat (BCX7353) is an oral, once-daily, h...

Acute urticaria in the infant.
https://doi.org/10.1111/pai.13350
Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology REFERENCES; Minasi D, Manti S et. al.

Nov 25th, 2020 - Urticaria is a mast cell-driven disease presenting with wheals, angioedema, or both. Acute urticaria (AU) lasts < 6 weeks. AU is a not common condition in newborns and infants since they are showing an immune system functionally insufficient. In n...

see more →

News  233 results

Fast Five Quiz: Food Allergies
https://reference.staging.medscape.com/viewarticle/936716_3

Sep 7th, 2020 - Although anaphylaxis can occur without skin symptoms, cutaneous reactions are the most common clinical manifestations of an allergic reaction to a food or food additive. Peanuts remain the most common cause of severe food allergy symptoms and anap...

Recurrent Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema Refractory to Fresh Frozen Plasma
https://www.mdedge.com/fedprac/article/213630/hospital-medicine/recurrent-angiotensin-converting-enzyme-inhibitor-induced/page/0/1?channel=327

Dec 5th, 2019 - Discussion The standard therapy for ACEI-inducedangioedema continues to be airway management and discontinuation of medication. However, life-threatening progression of symptoms have led to the use of off-label therapies, including FFP and bradyki.

FDA Drug Approvals: Pediatrics — Year in Review 2018
https://reference.medscape.com/viewarticle/907375

Jan 14th, 2019 - New Antimicrobials New tetracyclines and antimicrobials for influenza, malaria, onchocerciasis, smallpox, and more New Drugs in Oncology and Hematology Include a wide range of targeted therapies and first-in-class agents New Drugs in Immunology Ne...

HAE Attacks Cut With Lanadelumab
https://www.medpagetoday.com/rheumatology/generalrheumatology/76622

Nov 30th, 2018 - Action Points Patients with type I or type II hereditary angioedema (HAE) suffer from regular, unpredictable and life-disrupting attacks, and patients are in need of better drugs to control this lifelong disabling condition. Patients whose HAE is ...

Trial Data Back Lanadelumab for HAE Prevention
https://www.medpagetoday.com/rheumatology/generalrheumatology/76542

Nov 27th, 2018 - Prophylactic treatment with lanadelumab (Takhzyro) prevented hereditary angioedema attacks and led to a clinically-meaningful impact on quality of life, according to the pivotal HELP trial that led to recent FDA approval. The monoclonal antibody c...

see more →

Patient Education  9 results see all →